BD, Pfizer, Wellcome want to improve hospitals’ antimicrobial practices

By Sean Whooley | January 12, 2022

[Image from BD]

BD (NYSE:BDX) announced yesterday that it will collaborate with Pfizer (NYSE:PFE) and Wellcome to advance antimicrobial stewardship practices.

The collaboration builds on ongoing efforts to advance the role of diagnostics in addressing the challenge of antimicrobial resistance (AMR), according to a news release. The companies will survey existing diagnostic practices to highlight benefits and gaps in diagnostic testing in AMR stewardship to improve and advocate for patient care, clinical practice and healthcare economics.

Get the full story at our sister site, Medical Design & Outsourcing.

Filed Under: Drug Discovery and Development
Tagged With: BD, Pfizer, Wellcome

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.